<b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/>BGFV +11.8%, X +11.8%, BBOX +11.1%, BGS +10.2%, QLYS +7.8%, KAR +7.8%, (also increases quarterly dividend to $0.35/share, prior $0.32/share), SODA +7.5%, MOD +6.9%, NFX +6.5%, AMRN +5.9%, SCMP +5%, EL +4.7%, GNRC +4.7%, GRMN +4.2%, BBG +3.9%, ICPT +3.8%, SYX +3.2%, MDR +2.4%, APO +2%, WFT +2%, CHRW +1.6%, SB +1.4%, SSW +1.3%, FTR +1.2%, AGN +1.2%, CLX +1.2%, TEX +1%, IOVA +1%, VOYA +0.8%<br/><b>Select Macau related names showing strength following Macau data:</b><br/>MLCO +4.7%, WYNN +3.1%, LVS +2.5%, MGM +2.4%<br/>Select metals/mining stocks trading higher:<br/>AU +2.4%, HMY +2.3%, IAG +1.8%, GG +1.7%, ABX +1%, GDX +1%, GOLD +0.9%, GLD +0.5%, GFI +0.5%<br/><b>Other news:</b><br/>AVGR +25% (receives 510(k) clearance from the FDA for modifications to the company's Pantheris Lumivascular atherectomy system)<br/>ARQL +17.8% (FDA has granted Rare Pediatric Disease Designation to miransertib for the treatment of Proteus syndrome)<br/>MBRX +11.9% (announces that responses to the FDA requests for additional information relating to the IND application to study WP1066 as a potential treatment for brain tumors have been submitted)<br/>WPRT +9.8% (BRC Gas Equipment was awarded a competitive tender bid by Algeria's National Company for Petroleum Products Marketing and Distribution)<br/>WWR +9.5% (reports exploration results in the Columbus Basin)<br/>PTI +6.4% (initiates a 'strategic prioritization to focus resources on the research and development of its cystic fibrosis programs ' )<br/>TROV +5.6% (withdraws Registration Statement on Form S-3 initially filed with the Commission on September 29, 2017)<br/>AKS +4.4% (in sympathy with X earnings)<br/>RDHL +2.7% (resubmitted the 505(b)(2) New Drug Application (NDA) for RIZAPORT 10mg to the FDA)<br/>WBAI +2.4% (Chairman of the Board and Co-President of Tsinghua Unigroup has stepped down)<br/>MDR +2.4% (awarded significant contract from Reliance Industries)<br/>PHG +1.6% (pulling back on light volume; District Court enters permanent injunction against Philips North America and two executives to limit distribution of adulterated external defibrillators)<br/>NUE +1.3% (in sympathy with X earnings)<br/>AGN +1.2% (presented new analyses of VENUS II, the second of two pivotal Phase 3 clinical trials)<br/><b>Analyst comments:</b><br/>AAL +2.9% (upgraded to Overweight from Neutral at JP Morgan)<br/>MOS +1.1% (upgraded to Sector Perform from Underperform at Scotia)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/>EVHC -34.7%, DDD -18.1%, PBI -12.2%, WNC -10%, CHKP -8.7%, NVMI -8%, SGRY -7.6%, CSTE -7.6%, RGR -7.2%, CRTO -6.6%, QUAD -5.7%, FORM -5.5%, PAYC -5.1%, FISV -4%, HCLP -3.3%, COTV -3.3%, (also announces that Bradley Ferguson has been named Senior Vice President and Chief Financial Officer of the company, effective November 6, 2017), PZZA -2.9%, EA -2.7%, SPAR -2.5%, IPHI -2.4%, APC -2.1%, SENS -2.1%, LDL -2.1%, LFUS -1.2%, ENLC -1%, ALE -0.9%<br/><b>Other news:</b><br/>PRKR -11% (files for 4 mln share common stock offering by Aspire Capital; company may receive proceeds of up to $20.0 million pursuant to common stock purchase agreement)<br/>MRNS -4.3% (files $200 mln mixed securities shelf offering)<br/>SSYS -4.3% (following DDD results)<br/>XONE -3.6% (following DDD results)<br/>BLRX -2.9% (entered into $30 mln at-the-market sales agreement with BTIG)<br/>AOBC -2.3% (RGR sympathy)<br/>CDXC -1.5% (files for 1,965,417 share common stock offering by selling stockholders), .<br/><b>Analyst comments:</b><br/>ANF -6.2% (downgraded to Underweight from Neutral at JP Morgan)<br/>I -3% (downgraded to Sell at UBS)<br/>EXAS -2.2% (downgraded to Neutral at BTIG Research)<br/>DSW -1.8% (downgraded to Neutral from Outperform at Wedbush)<br/>JBLU -0.9% (downgraded to Neutral from Overweight at JP Morgan)<br/>MCHP -0.9% (downgraded to Equal-Weight from Overweight at Morgan Stanley)<br/>GT -0.9% (downgraded to Neutral from Buy at Guggenheim)<br/>UAL -0.6% (downgraded to Underweight from Neutral at JP Morgan)<br/><br/>Briefing.com